Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials.

Takumi KawaguchiFumitaka SuzukiMasatoshi ImamuraNaoya MurashimaMikio YanaseTetsuya MineMasaki FujisawaIkuya SatoHitoshi YoshijiKiwamu OkitaKazuyuki Suzuki

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)

We report clinical profiles associated with gut bacterial loads in patients with HE, and showed that RFX altered gut microbiota components associated with liver/neuropsychological functions. Thus, RFX could improve liver/neuropsychological functions through the regulation of the gut microbial consortia in patients with HE.

Keyphrases

phase ii
clinical trial
mild cognitive impairment
open label
randomized controlled trial
machine learning
double blind
study protocol
deep learning
artificial intelligence